← 返回

通过 CXCR4 和 PD-1 阻断靶向胰腺导管腺癌中基质介导的 T 细胞排斥和功能性耗竭

英文原题:Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade.

查看英文原题

Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade.

PubMed 2026/07/21(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的研究结果确定了 PDAC 中 T 细胞功能障碍的关键决定因素,并引入了一种多功能的、非动物的 3D 模型,该模型有力地捕捉了 PDAC 中标志性的免疫逃逸机制。该系统为剖析 TME 驱动的免疫抑制以及加速免疫治疗策略(包括患者定制方法)的功能评估提供了一种可扩展且机制忠实的工具。

研究思路结论见上方概要

胰腺导管腺癌(PDAC)是迄今为止最致命的恶性肿瘤之一,其特征是独特的免疫抑制和高度促结缔组织增生的肿瘤微环境(TME)。这些特征驱动了深刻的T细胞功能障碍,并维持对当前免疫治疗的高度耐药。通过重现人PDAC的复杂3D结构,我们展示了在肿瘤微环境中驱动T细胞功能障碍的关键免疫抑制机制。

由单独 PANC-1 细胞或与原发性胰腺星状细胞(PSC)共同生成的 3D PDAC 球体,被来自健康供体的原代人 T 细胞浸润,从而能够对 T 细胞浸润、激活和检查点调控进行受控分析。此外,由原发性肿瘤细胞和癌症相关成纤维细胞组成的患者来源球体(PDS)被自体 T 细胞浸润。

浸润的T细胞表现出显著的耗竭特征,包括PD-1、LAG-3和CTLA-4的强烈上调,与从PDAC患者样本中分离的TIL(肿瘤浸润淋巴细胞)的表型高度相似。胰腺星状细胞(PSC)的加入在肿瘤细胞周围形成了纤维化屏障,显著限制了T细胞浸润,模拟了PDAC特征性的促结缔组织增生性TME。从机制角度看,基质CXCL12-CXCR4增强了T细胞排斥:使用AMD3100进行药理学CXCR4阻断显著增强了T细胞向含PSC球状体的浸润。此外,抗PD-1单克隆抗体pembrolizumab治疗部分恢复了3D系统中T细胞的效应细胞功能。这些结果表明,该简化平台能够捕捉通常仅在晚期类器官或体内系统中观察到的复杂、细胞因子和基质驱动的免疫调节。至关重要的是,关键免疫学特征——包括T细胞耗竭、基质排斥和治疗反应性——在PDS中得到了完全重现。PDS重现了患者特异性的T细胞抑制模式和治疗反应,凸显了该平台的转化相关性。

展开英文摘要原文

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies to date and characterized by a unique immunosuppressive and highly desmoplastic tumor microenvironment (TME). These features drive profound T-cell dysfunction and maintain high resistance to current immunotherapy. By recapitulating the complex 3D architecture of human PDAC, we demonstrate the key immunosuppressive mechanisms that drive T-cell dysfunction within the tumor microenvironment. METHOD: 3D PDAC spheroids-generated from PANC-1 cells alone or together with primary pancreatic stellate cells (PSC)-were infiltrated with primary human T-cells from healthy donors, allowing controlled analysis of T-cell infiltration, activation, and checkpoint regulation. Furthermore, patient-derived spheroids (PDS) composed of primary tumor cells and cancer-associated fibroblasts were infiltrated with autologous T-cells.

Infiltrated T-cells exhibited a pronounced exhaustion signature, including strong upregulation of PD-1, LAG-3, and CTLA-4, closely mirroring the phenotype of tumor-infiltrating lymphocytes (TIL) isolated from PDAC patient samples. Incorporation of pancreatic stellate cells (PSC) generated a fibrotic barrier around the tumor cells that markedly restricted T-cell infiltration, modeling the desmoplastic TME characteristic of PDAC. From a mechanistic perspective, stromal CXCL12-CXCR4 enhanced T-cell exclusion: pharmacological CXCR4 blockade with AMD3100 significantly enhanced T-cell infiltration into PSC-containing spheroids. Furthermore, treatment with the anti-PD-1 monoclonal antibody pembrolizumab partially restored the effector cell function of T-cells within the 3D system. These results demonstrate that this minimalistic platform is capable of capturing complex, cytokine- and stroma-driven immunomodulation typically observed only in advanced organoid or in vivo systems. Crucially, key immunological features-including T-cell exhaustion, stromal exclusion, and therapeutic responsiveness-were fully reproduced in PDS. PDS reproduced patient-specific T-cell suppression patterns and therapeutic responses, underscoring the translational relevance of the platform.

Together, our findings identify critical determinants of T-cell dysfunction in PDAC and introduce a versatile, animal-free 3D model that powerfully captures hallmark immune-evasion mechanisms in PDAC. This system provides a scalable and mechanistically faithful tool for dissecting TME-driven immune suppression and for accelerating the functional evaluation of immunotherapeutic strategies, including patient-tailored approaches.

论文信息

作者
Deipenbrock A、Hofer L、Wilmes BE、Cetin T、Esposito I、Weyhe D、Stegmaier J、Teusch NE
单位
Heinrich-Heine-Universität Düsseldorf, Institute of Pharmaceutical Biology and Biotechnology, Düsseldorf, North Rhine-Westphalia, Germany.Germany
期刊
Frontiers in immunology2026
原文标识
PubMed 42553398 · DOI 10.3389/fimmu.2026.1844781